Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.

[1]  R. Wirtz,et al.  Comparison of immunoreactive score, HER2/neu score and H score for the immunohistochemical evaluation of somatostatin receptors in bronchopulmonary neuroendocrine neoplasms , 2015, Histopathology.

[2]  R. Rocha,et al.  Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast , 2015, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[3]  V. Borges,et al.  Physiological COX-2 expression in breast epithelium associates with COX-2 levels in ductal carcinoma in situ and invasive breast cancer in young women. , 2014, The American journal of pathology.

[4]  Ling Wei,et al.  Expressions of ER, PR, HER-2, COX-2, and VEGF in Primary and Relapsed/Metastatic Breast Cancers , 2014, Cell Biochemistry and Biophysics.

[5]  C. Ingvar,et al.  Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients , 2014, International journal of cancer.

[6]  J. Bharti,et al.  Evaluation of p53, HoxD10, and E-Cadherin Status in Breast Cancer and Correlation with Histological Grade and Other Prognostic Factors , 2014, Journal of oncology.

[7]  D. Noonan,et al.  Paradoxic effects of metformin on endothelial cells and angiogenesis , 2014, Carcinogenesis.

[8]  Hiroko Yamashita,et al.  p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors , 2013, Cancer science.

[9]  H Tesch,et al.  Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Suhas D. Doke,et al.  Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers , 2013, Oncology letters.

[11]  Ling Zhou,et al.  Novel prognostic markers for patients with triple-negative breast cancer. , 2013, Human pathology.

[12]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Ling Zhou,et al.  Molecular markers of therapeutic resistance in breast cancer. , 2013, Human pathology.

[14]  M. Mandal,et al.  Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling , 2013, BMC Cancer.

[15]  C. Perou,et al.  Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Nesland,et al.  Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact. , 2012, Histology and histopathology.

[17]  K. Khazaie,et al.  Regulation of COX2 Expression in Mouse Mammary Tumor Cells Controls Bone Metastasis and PGE2-Induction of Regulatory T Cell Migration , 2012, PloS one.

[18]  J. Sandbank,et al.  COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients , 2012, Medical Oncology.

[19]  B. Rigas,et al.  Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents , 2012, Journal of Pharmacology and Experimental Therapeutics.

[20]  A. Cecchini,et al.  Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients , 2012, Cancer Immunology, Immunotherapy.

[21]  B. Biesaga,et al.  Microvessel Density and Status of p53 Protein as Potential Prognostic Factors for Adjuvant Anthracycline Chemotherapy in Retrospective Analysis of Early Breast Cancer Patients Group , 2012, Pathology & Oncology Research.

[22]  L. Sarian,et al.  Expression of cyclooxygenase-2 (COX-2) and p53 in neighboring invasive and in situ components of breast tumors. , 2012, Acta histochemica.

[23]  Panagiotis Dendrinos,et al.  The Structure of Mediterranean Rocky Reef Ecosystems across Environmental and Human Gradients, and Conservation Implications , 2012, PloS one.

[24]  W. Han,et al.  COX2 overexpression is a prognostic marker for Stage III breast cancer , 2012, Breast Cancer Research and Treatment.

[25]  S. O'toole,et al.  Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53 , 2011, British Journal of Cancer.

[26]  M. Cantwell,et al.  A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer , 2011, British Journal of Cancer.

[27]  Charles M Perou,et al.  Molecular stratification of triple-negative breast cancers. , 2010, The oncologist.

[28]  T. Aoki,et al.  Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer. , 2010, Revista do Colegio Brasileiro de Cirurgioes.

[29]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[30]  Charles M. Perou,et al.  Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.

[31]  J. Wesseling,et al.  p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. , 2007, The Journal of surgical research.

[32]  M. C. Lee,et al.  Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. , 2006, Breast.

[33]  T. Sørlie,et al.  Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms , 2006, BMC Genomics.

[34]  P. Ongusaha,et al.  p53‐mediated induction of Cox‐2 counteracts p53‐ or genotoxic stress‐induced apoptosis , 2002, The EMBO journal.

[35]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[37]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  W. Remmele,et al.  Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). , 1993, Pathology, research and practice.

[39]  J. Wesseling,et al.  p 53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast , 2018 .

[40]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[41]  M. Gilcrease.  Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer , 2013 .

[42]  K. Hess,et al.  DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. , 2011, The oncologist.

[43]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .